We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Plasmodium vivax Isolated in Duffy Negative Individuals

By LabMedica International staff writers
Posted on 12 Dec 2018
Malaria in Nigeria is principally due to Plasmodium falciparum and, to a lesser extent to P. More...
malariae and P. ovale. P. vivax is thought to be absent in Nigeria in particular and sub-Saharan Africa in general, due to the near fixation of the Duffy negative gene in this population.

Microscopy which is the gold standard for malaria diagnosis can detect Plasmodium infections in individuals with high level of parasitaemia; however parasite detection in individuals carrying low parasite density can be challenging, thus emphasizing the need for more sensitive diagnostic methods.

Medical parasitologists at the Université Cheikh Anta Diop (Dakar, Senegal) carried out a cross-sectional investigation involving 436 febrile patients were included for the present work patients presenting clinical symptoms of malaria and visiting any of the various hospitals in two study sites between September 2016 to March 2017. Venous blood of these patients was subjected to a P. falciparum specific HRP2 rapid diagnostic test, as well as microscopy.

Parasite DNA was isolated from positive samples and polymerase chain reaction (PCR) diagnostic was employed followed by direct sequencing of the 18S rRNA of Plasmodium species as well as sequencing of a portion of the promoter region of the Duffy antigen receptor for chemokines. Samples positive for P. vivax were re-amplified several times and finally using the High Fidelity Taq to rule out any bias introduced. In order to validate the different species identified by PCR in gel electrophoresis, the 18S rRNA gene of P. vivax and the DARC-coding gene of the P. vivax infected individuals were sequenced commercially by Inqaba Biotec.

The team reported that of the 256 (58.7%) amplifiable malaria parasite DNA, P. falciparum was, as expected, the major cause of infection, either alone 85.5% (219/256), or mixed with P. malariae 6.3% (16/256) or with P. vivax 1.6% (4/256). Only one of the five P. vivax isolates was found to be a single infection. DNA sequencing and subsequent alignment of the 18S rRNA of P. vivax with the reference strains displayed very high similarities (100%). Remarkably, the T-33C mutation was identified in all P. vivax samples, thus confirming that all vivax-infected patients in the current study are Duffy negative.

The authors concluded that given the fact that Nigeria accounts for 27% of the global malaria burden mostly due to P. falciparum, the addition of P. vivax to this, will ultimately add to the burden of country’s struggle to control malaria and the defensive barrier hypothesis against P. vivax infection due to the near fixation of the Duffy-negative gene in the African population should be investigated. The study was published on November 28, 2018, in the Malaria Journal.

Related Links:
Université Cheikh Anta Diop


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR Setup
ESTREAM
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.